Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL15-DC Vaccine in High Risk Melanoma
NCT01189383Phase 2Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jan 2011
- Primary completion
- Dec 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of IL15-DC Vaccine in melanoma, sponsored by Baylor Scott & White Research Institute. Started Jan 2011; status: completed.
02
Drugs
IL15-DC Vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01189383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189383.